Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lang

Showing results (281-290 of 312) with videos related to

Pageof 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 21, 2019
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 studyAnna Maria Testi, Andishe Attarbaschi, Maria Grazia Valsecchi, et al.
Journal for Immunotherapy of Cancer|May 21, 2026
Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohortAnna-Sophia Mast, Peter Lang, Patrick Schlegel, et al.
Haematologica|May 14, 2016
Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter surveyZyrafete Kuçi, Halvard Bönig, Hermann Kreyenberg, et al.
The New England Journal of Medicine|September 18, 2024
Newborn Screening and Presymptomatic Treatment of Metachromatic LeukodystrophyLucia Laugwitz, Thomas P Mechtler, Nils Janzen, et al.
Frontiers in Bioengineering and Biotechnology|April 28, 2022
Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell TherapyAgnes Bonifacius, Sabine Tischer-Zimmermann, Maria Michela Santamorena, et al.
Blood Advances|August 27, 2025
Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene AutotemcelJosu de la Fuente, Haydar Frangoul, Peter Lang, et al.
British Journal of Haematology|July 21, 2018
Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trialMichaela Kuhlen, Peter Bader, Martin Sauer, et al.
Bone Marrow Transplantation|February 22, 2023
Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working PartyRaffaella Greco, Jorinde D Hoogenboom, Edouard F Bonneville, et al.
Scientific Reports|July 18, 2025
Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed familiesAlex Dulovic, Armin Rabsteyn, Jonathan Remppis, et al.
Blood|April 22, 2016
The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosisBernd Hartz, Rebecca Marsh, Kanchan Rao, et al.
Pageof 32

Showing results (281-290 of 312) with videos related to

Sort By:
Pageof 32
European Journal of Cancer (Oxford, England : 1990)|October 21, 2019
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 studyAnna Maria Testi, Andishe Attarbaschi, Maria Grazia Valsecchi, et al.
Journal for Immunotherapy of Cancer|May 21, 2026
Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohortAnna-Sophia Mast, Peter Lang, Patrick Schlegel, et al.
Haematologica|May 14, 2016
Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter surveyZyrafete Kuçi, Halvard Bönig, Hermann Kreyenberg, et al.
The New England Journal of Medicine|September 18, 2024
Newborn Screening and Presymptomatic Treatment of Metachromatic LeukodystrophyLucia Laugwitz, Thomas P Mechtler, Nils Janzen, et al.
Frontiers in Bioengineering and Biotechnology|April 28, 2022
Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell TherapyAgnes Bonifacius, Sabine Tischer-Zimmermann, Maria Michela Santamorena, et al.
Blood Advances|August 27, 2025
Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene AutotemcelJosu de la Fuente, Haydar Frangoul, Peter Lang, et al.
British Journal of Haematology|July 21, 2018
Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trialMichaela Kuhlen, Peter Bader, Martin Sauer, et al.
Bone Marrow Transplantation|February 22, 2023
Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working PartyRaffaella Greco, Jorinde D Hoogenboom, Edouard F Bonneville, et al.
Scientific Reports|July 18, 2025
Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed familiesAlex Dulovic, Armin Rabsteyn, Jonathan Remppis, et al.
Blood|April 22, 2016
The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosisBernd Hartz, Rebecca Marsh, Kanchan Rao, et al.
Pageof 32